Reported 1 day ago
Hims & Hers Health shares surged on Tuesday after the telehealth platform announced the inclusion of Eli Lilly's weight-loss medication Zepbound and diabetes treatment Mounjaro, both priced at $1,899 monthly. This addition marks a significant boost as Hims stock has more than doubled in the past year, even amidst recent market fluctuations related to the FDA's comments on diabetes drug shortages.
Source: YAHOO